Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer

Fang He\textsuperscript{1,2} | Li Yu\textsuperscript{3} | Yi Ding\textsuperscript{4} | Zhen-Hui Li\textsuperscript{5} | Jian Wang\textsuperscript{6} | Jian Zheng\textsuperscript{1} | Hai-Yang Chen\textsuperscript{1} | Shuai Liu\textsuperscript{1} | Xiao-Lin Pang\textsuperscript{1} | Jaffer A. Ajani\textsuperscript{7} | Xiang-Bo Wan\textsuperscript{1,2} 

\textsuperscript{1}Department of Radiation Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 
\textsuperscript{2}Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, Guangzhou, China 
\textsuperscript{3}Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China 
\textsuperscript{4}Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China 
\textsuperscript{5}Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China 
\textsuperscript{6}Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China 
\textsuperscript{7}Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence
Jaffer A. Ajani, Department of Gastrointestinal Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. 
Email: jajani@mdanderson.org

and

Xiang-Bo Wan, Mailing address: Department of Radiation Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. 
Email: wanxbo@mail.sysu.edu.cn

Abstract
Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision and adjuvant chemotherapy is the standard regimen for patients with locally advanced rectal cancer (LARC). However, whether and to which extent neoadjuvant radiotherapy could be removed from nCRT for patients with LARC is still unclear. This was a multicenter, retrospectively recruited, prospectively maintained cohort study. A propensity score matching model was employed to minimize potential confounding factors between subgroup patients treated with neoadjuvant chemotherapy (nCT) or nCRT. Overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed between subgroup patients by Kaplan-Meier analysis, log-rank test, and Cox regression model. In total, 3233 consecutive patients, consist of 571 nCT and 2662 nCRT-treated cases, were included. After propensity score matching (1:4), 565 nCT-treated patients were matched to 1852 nCRT-treated patients. Compared with nCT, nCRT treatment indeed decreased 3-y local recurrence (10.0% vs 6.6%, \( P = 0.026 \)), but had no impact on OS, DFS and DMFS (all \( P > 0.05 \)) for LARC. Stratified analysis further confirmed that nCRT treatment was associated with higher 3-y LRFS and 3-y DFS than nCT-treated cases, were included. After propensity score matching (1:4), 565 nCT-treated patients were matched to 1852 nCRT-treated patients. Compared with nCT, nCRT treatment indeed decreased 3-y local recurrence (10.0% vs 6.6%, \( P = 0.026 \)), but had no impact on OS, DFS and DMFS (all \( P > 0.05 \)) for LARC. Stratified analysis further confirmed that nCRT treatment was associated with higher 3-y LRFS and 3-y DFS than nCT treatment for baseline high-risk subgroup (cT4, cN+, and cIII stage) patients (all \( P < 0.05 \)). Conversely, for the baseline low-risk subgroup patients (cT3, cN0, and cII stage), nCRT and nCT treatment had similar 3-y OS, LRFS, DFS, and DMFS (all \( P > 0.05 \)). The administration of neoadjuvant radiotherapy for LARC patients might be determined by baseline risk classification, the high-risk individuals could be delivered while low-risk patients might be omitted.

Abbreviations: CI, confidence interval; CRM, circumferential resection margin; CT, computed tomography; DFS, disease-free survival; DMFS, distant metastasis-free survival; HR, hazard ratios; LARC, locally advanced rectal cancer; LRFS, local recurrence-free survival; nCRT, neoadjuvant chemoradiotherapy; NCT, neoadjuvant chemotherapy; OS, overall survival; pCR, pathologic complete response; TME, total mesorectal excision.

Fang He, Li Yu, Yi Ding, and Zhen-Hui Li are contributed equally.
1 | INTRODUCTION

Currently, nCRT followed by TME surgery and postoperative chemotherapy is the standard regimen for patients with LARC.\textsuperscript{1,2} Previously, the Swedish Rectal Cancer Trial confirmed that, compared with surgery alone, neoadjuvant radiotherapy significantly decreased the local recurrence for LARC (26.9\% vs 11.4\%).\textsuperscript{3} Similarly, the Dutch Colorectal Cancer Group Trial, the largest phase III trial in the TME era, reported that their 10-\text{y} cumulative local recurrence rate was 11.0\% in the TME operation subgroup alone and 5.0\% in the short-term radiotherapy (5 ≤ 5 Gy) subgroup.\textsuperscript{4} Furthermore, CAO/ARO/AIO-94\textsuperscript{5} and NSABP R-03\textsuperscript{6} trials found that, although it did not have OS benefit, concurrent nCRT treatment resulted in lower recurrence within the pelvic area for patients compared with those given adjuvant chemotherapy alone (6.0\%-13.0\% vs 23.9\%-27.5\%). Hence, the benefit of neoadjuvant radiotherapy mainly lies in reducing local recurrence for patients with LARC.

Supported by the development of a standard TME surgery protocol and en bloc removal of a gross tumor mass, clearance of local micrometastatic deposits as well as lymph nodes is guaranteed. Given the overlapping function of TME surgery and preoperative radiotherapy in local control, a strategy of removing neoadjuvant radiotherapy by intensified neoadjuvant chemotherapy (nCT) was raised for LARC, aiming to achieve both favorable local control and a high quality of life. Prospective trials, such as STAR-01,\textsuperscript{6} NSABP R-04,\textsuperscript{7} the German CAO/ARO/AIO-04,\textsuperscript{8,9} and FORWAC,\textsuperscript{10} have enlightened us to the fact that the combination of more powerful nCT treatment with or without target therapy might be a promising way to reduce distant metastasis and improve oncological outcomes for LARC.\textsuperscript{11,12} Taking the German CAO/ARO/AIO-04 study for example, adding oxaliplatin to fluorouracil-based nCRT and adjuvant chemotherapy significantly improved DFS for cT3-4 or cN1-2 LARC patients.\textsuperscript{9} In contrast, several trials also confirmed that aggressive nCT only increased acute toxicity, however it failed to increase the proportion of pathologic complete responses (pCR) or to improve survival.\textsuperscript{7,10} Therefore, the efficacy of nCT and nCRT treatment remained controversial in patients with LARC.

Here, based on a retrospectively recruited, prospectively maintained, multicenter LARC patient cohort, the survival outcomes (OS, DFS, LRFS and DMFS) between subgroup patients given neoadjuvant radiochemotherapy or systemic neoadjuvant chemotherapy were compared using a propensity score matching approach.

2 | MATERIAL AND METHODS

2.1 | Patients

This study recruited patients with LARC (clinically T3-T4 and/or N-positive) within 15 cm of anal verge from January 2010 through December 2018. Patients were all histologically confirmed as having rectal adenocarcinoma. Prior to neoadjuvant treatment, contrast-enhanced pelvic magnetic resonance imaging, transrectal ultrasound, and enteroscopy were performed to evaluate the tumor invasion area. The clinical stage of each LARC patient was defined based on the American Joint Committee on Cancer TNM classification system (8th edition), by retrospectively reviewing contrast-enhanced pelvic magnetic resonance imaging.\textsuperscript{13} The exclusion criteria consisted of patients with non-adenocarcinoma, distant metastasis at diagnosis, stage I or IV, R1 or R2 resection, prior history of malignancy, Eastern Cooperative Oncology Group Performance Status ≥ 2, or without TME surgery. This study was approved by the Clinical Ethics Review Committee of the Sixth Affiliated Hospital of Sun Yat-sen University (No. 2019ZSLYEC-137).

2.2 | Treatment

All LARC patients received nCRT or nCT, followed by TME surgery with or without adjuvant chemotherapy subsequently. Briefly, neoadjuvant radiotherapy was delivered by direct beam radiation of 50.0 Gy in 25 fractions, and patients were concurrently given fluoropyrimidine-based chemotherapy.\textsuperscript{10} After a 6-8 wk waiting time, the concurrent nCRT-treated patients received the standard TME surgery under the protocol we previously described.\textsuperscript{10} nCT was administered with a fluorouracil-based FOLFOX or CAPOX regimen, while the regimen and cycles delivered were determined at the multidiscipline team (MDT)'s discretion. At 2 wk after completion of nCT, patients received a standard TME operation. The TME surgery specimen was pathologically evaluated by the American Joint Committee on Cancer and College of American Pathologists tumor regression grade (AJCC/CAP TRG) system.\textsuperscript{14} At 2-4 wk later, the
fluoropyrimidine-based adjuvant chemotherapy was administered. The adjuvant chemotherapeutic regimen and cycles to be given were at the institutional MDT’s discretion.

2.3 | Follow-up

After TME surgery, all patients were followed up at 3-mo intervals during the first 3 y and at 6-mo intervals thereafter. At each follow-up, physical examination, complete biochemistry, and tumor biomarkers test were regularly monitored. Contrast-enhanced pelvic magnetic resonance imaging and colonoscopy was performed annually at the first 3 y. The latest date of each patient being followed up was August 1, 2019. Specifically, OS was defined as time to death, or when censored at the latest date if patients were still alive. DFS was defined as time to the date of disease relapse, or the date of death or when censored at the latest date. LRFs and DMFS were defined as time to the date of local recurrence or distant metastases, respectively, or date of death or when censored at the latest date.

2.4 | Propensity score matching

The propensity scores model was employed to match the potential bias of confounding covariates between nCRT and nCT subgroup patients. Firstly, a multivariable logistic regression model was constructed to generate propensity scores. The propensity score model was performed by matching the potential confounding clinicopathological factors, including of age (≤55 y vs >55 y) at diagnosis, sex (male vs female), clinical stage (II vs III), clinical T stage (T3 vs T4), clinical N stage (N0 vs N+), histologic grade (well, moderately, poorly differentiated), tumor distance from anus (≤ 5, 6-10, >10 cm), nCT (with vs without), nCT cycles (0, 1-4, >4), CRM (negative vs positive), ypT, ypN, ypTNM stage, adjuvant chemotherapy (with vs without), and cycle of adjuvant chemotherapy (0, 1-4, >4). The nCT and nCRT-treated subgroup patients were matched at 1:4 ratio, using a greedy, nearest neighbor matching algorithm with no replacement. A caliper width equal to 0.2 of the standard deviation was utilized as the logit of the propensity score. Patient characteristics between the propensity score-matched subgroups were compared using the P-value.

2.5 | Statistical analysis

Kaplan-Meier survival curves were used to compare OS, DFS, DMFS, and LRFs between the subgroup patients. Statistical differences between curves were calculated using the log-rank test. The chi-square test was performed to compare each clinicopathological variable. The multivariate Cox proportional hazards model was used to estimate the HR and 95% CI for patient outcome. All P-values quoted were two-sided. A P-value less than .05 was considered as statistically different. Statistical analysis was performed using SPSS (version 24.0; SPSS, Inc).

3 | RESULTS

3.1 | Patient characteristics

In total, 3233 consecutively enrolled patients with LARC were included in this study (median age, 55.0 y; 67.7% of male). Of these, 571 (17.7%) patients were given nCT solely (range, 1-12 cycles; median, 4 cycles), and the remaining 2662 (82.3%) patients were treated with concurrent nCRT (range, 1-12 cycles; median, 3 cycles). Specifically, tumor located at 0-5 cm from anal verge, clinical III (cIII) stage, cT3, cT4, cN0, cN1 and cN2 stages were noted at 40.2%, 73.9%, 75.8%, 21.4%, 26.1%, 73.9%, and 0.0% in nCT subgroup patients, and at 55.1%, 79.6%, 62.4%, 33.7%, 20.4%, 79.0%, and 0.6% in nCRT subgroup patients, respectively. Moreover, pCR was observed in 17.3% (99/571) of nCT subgroup patients, and in 27.3% (728/2662) of nCRT subgroup patients (P < .001). Significantly, compared with patients who received nCT treatment, nCRT-treated patients always had a favorable ypT, ypN and AJCC/CAP TRG category (all P < .05) (Table 1).

At 1:4 propensity score matching, 565 nCT-treated patients were matched to 1852 patients who received nCRT treatment. As shown in Table 1, after propensity score matching, the standardized differences of included covariates between these 2 subset patients were all less than 0.1 (Figure S1), suggesting a well balanced covariates distribution.

3.2 | Survival analyses

The median follow-up time of the entire cohort was 40.0 mo (range, 3.0 to 148.0 mo). At 1:4 matching, the 3-y OS ratio between these 2 subgroup patients did not reach a significant difference (Figure 1A): the 3-y OS rate was 93.9% for the nCT subgroup patients, and 90.6% for the nCRT subgroup patients (P = .062). Moreover, patients treated with or without neoadjuvant radiotherapy had a comparable 3-y DFS (Figure 1B): the 3-y DFS rate was 73.5% for the nCT subgroup patients, and 77.3% for the nCRT subgroup patients (P = .057). Additionally, these 2 subgroup patients had a similar 3-y DMFS (nCT vs nCRT, 78.3% vs 80.6%, P = .26; Figure 1C). Significantly, compared with nCT, nCRT treatment was correlated with an improved 3-y LRFS (nCRT vs nCT, 93.4% vs 90.0%, P = .026. HR, 1.450; 95% CI, 1.044-2.013; Figure 1D).

3.3 | Stratified survival analyses

In light of baseline cIII, cT4 and cN+ stage, subgroup patients had a high risk of developing disease progression,9,15-17 stratified survival analyses (all at 1:4 propensity score matching) were
| Characteristics | Before Matching | After Matching (1:4) |
|-----------------|-----------------|---------------------|
|                 | nCT No. (%) (n = 571) | nCRT No. (%) (n = 2662) | P-value | nCT No. (%) (n = 565) | nCRT No. (%) (n = 1852) | P-value |
| Age, median 55 y |                 |                     |         |                     |                     |         |
| ≤55             | 276 (48.3)       | 1271 (47.7)         | .798    | 273 (48.3)          | 883 (47.7)          | .790    |
| >55             | 296 (51.7)       | 1391 (52.3)         |         | 292 (51.7)          | 969 (52.3)          |         |
| Gender          |                 |                     |         |                     |                     |         |
| Male            | 391 (68.5)       | 1797 (67.5)         | .653    | 388 (68.7)          | 1255 (67.8)         | .596    |
| Female          | 180 (31.5)       | 865 (32.5)          |         | 177 (31.3)          | 597 (32.2)          |         |
| Clinical T stage|                 |                     |         |                     |                     |         |
| cT1             | 1 (0.2)          | 7 (0.3)             | <.001   | 1 (0.2)            | 6 (0.3)             | .292    |
| cT2             | 15 (2.6)         | 97 (3.6)            |         | 14 (2.5)           | 87 (4.7)            |         |
| cT3             | 433 (75.8)       | 1660 (62.4)         |         | 430 (76.1)         | 1271 (68.7)         |         |
| cT4             | 122 (21.4)       | 898 (33.7)          |         | 120 (21.2)         | 488 (26.3)          |         |
| Clinical N stage|                 |                     |         |                     |                     |         |
| cN0             | 149 (26.1)       | 542 (20.4)          | .001    | 147 (26.0)         | 428 (23.1)          | .136    |
| cN1             | 422 (73.9)       | 2104 (79.0)         |         | 418 (74.0)         | 1421 (76.7)         |         |
| cN2             | 0 (0.0)          | 16 (0.6)            |         | 0 (0.0)            | 3 (0.2)             |         |
| Clinical TNM stage|               |                     |         |                     |                     |         |
| II              | 149 (26.1)       | 542 (20.4)          | .002    | 147 (26.0)         | 428 (23.1)          | .155    |
| III             | 422 (73.9)       | 2120 (79.6)         |         | 418 (74.0)         | 1361 (76.9)         |         |
| Location from anal verge, cm |                 |                     |         |                     |                     |         |
| 0-5             | 230 (40.2)       | 1468 (55.1)         | <.001   | 230 (40.7)         | 907 (49.0)          | .024    |
| 5-10            | 279 (48.9)       | 1028 (38.6)         |         | 276 (48.8)         | 795 (42.9)          |         |
| >10             | 52 (9.1)         | 87 (3.3)            |         | 52 (9.2)           | 77 (4.2)            |         |
| Unknown/missing | 10 (1.8)         | 79 (3.0)            |         | 7 (1.3)            | 73 (3.9)            |         |
| Tumor differentiation |               |                     |         |                     |                     |         |
| High-differentiated | 154 (27.0)      | 386 (14.5)          | <.001   | 150 (26.5)         | 340 (18.4)          | .005    |
| Median-differentiated | 348 (60.9)      | 1819 (68.3)         |         | 346 (61.3)         | 1297 (70.0)         |         |
| Low-differentiated | 69 (12.1)       | 457 (17.2)          |         | 69 (12.2)          | 215 (11.6)          |         |
| nCT or not      |                 |                     |         |                     |                     |         |
| NO NCT          | 0 (0.0)          | 55 (2.1)            | .001    | –                  | –                  | –       |
| NCT             | 571 (10.0)       | 2607 (97.9)         |         | 565 (100.0)        | 1852 (100.0)        |         |
| nCT cycle, median 4 cycles |             |                     |         |                     |                     |         |
| 0               | 0 (0.0)          | 55 (2.0)            | .009    | –                  | –                  | –       |
| 1-4             | 418 (73.2)       | 2028 (76.2)         |         | 413 (73.1)         | 1393 (75.2)         | .311    |
| ≥5              | 153 (26.8)       | 579 (21.8)          |         | 152 (26.9)         | 459 (24.8)          |         |
| Pathological T stage |             |                     |         |                     |                     |         |
| ypT0            | 99 (17.3)        | 728 (27.3)          | .001    | 99 (17.5)          | 412 (22.2)          | .226    |
| ypT1            | 38 (6.7)         | 143 (5.4)           |         | 37 (6.5)           | 99 (5.3)           |         |
| ypT2            | 125 (21.9)       | 572 (21.5)          |         | 123 (21.8)         | 426 (23.0)          |         |
| ypT3            | 269 (47.1)       | 916 (34.4)          |         | 266 (47.1)         | 696 (37.7)          |         |
| ypT4            | 40 (7.0)         | 303 (11.4)          |         | 40 (7.1)           | 219 (11.8)          |         |
| Pathological N stage |             |                     |         |                     |                     |         |
| ypN0            | 435 (76.2)       | 2090 (78.5)         | .063    | 433 (76.6)         | 1448 (78.1)         | .395    |
| ypN1            | 97 (17.0)        | 452 (17.0)          |         | 97 (17.2)          | 303 (16.4)          |         |

(Continues)
conducted to identify the subgroup that would benefit most from neoadjuvant radiotherapy. Compared with nCT treatment, concurrent nCRT treatment was associated with similar survival outcome (3-y OS, 3-y DFS, 3-y LRFS, and 3-y DMFS) (all P > .05; Figure S2).

As expected, for baseline cT4 stage patients, nCRT treatment was correlated with a favorable 3-y DFS (78.1% vs 68.0%, P = .028; HR, 0.648; 95% CI, 0.438-0.959; Figure 3B) and 3-y LRFS (92.1% vs 84.4%, P = .022; HR, 0.512; 95% CI, 0.285-0.917; Figure 3D) than nCT treatment. However, this difference was not observed at 3-y OS (P = .476; HR, 1.272; 95% CI, 0.655-2.470; Figure 3A) and 3-y DMFS (P = .050; HR, 0.657; 95% CI, 0.430-1.004; Figure 3C) for baseline cT4 stage patients given nCT or nCRT. Also, for baseline cT3 stage patients, nCT or nCRT
treatment had a comparable 3-y survival outcome (OS, DFS, LRFS, and DMFS, all $P > .05$; Figure S3).

Similarly, for baseline cN$^+$ stage patients, nCRT treatment was correlated with a prolonged 3-y DFS (77.0% vs 71.7%, $P = .024$; HR, 0.779; 95% CI, 0.626-0.969; Figure 4B) and 3-y LRFS (93.2% vs 88.7%, $P = .013$; HR, 0.635; 95% CI, 0.443-0.910; Figure 4D) than nCT treatment. By contrast, nCT and nCRT treatment achieved a comparable 3-y OS ($P = .262$; HR, 1.220; 95% CI, 0.861-1.728; Figure 4A) and 3-y DMFS ($P = .181$; HR, 0.851; 95% CI, 0.671-1.079; Figure 4C) for baseline cN$^+$ stage patients. Moreover, for baseline cN0 stage patients, nCT or nCRT treatment correlated with similar survival outcomes (3-y OS, 3-y DFS, 3-y LRFS, and 3-y DMFS) (all $P > .05$; Figure S4).

3.4 | Multivariate analysis

All clinicopathological factors that displayed significance in univariate analysis were subjected to the Cox regression multivariate analysis (Figure S5). As shown in Table 2, AJCC/CAP TRG system, tumor location, tumor differentiation status, neoadjuvant treatment regimen, ypT stage, and ypN stage were the independent factors to predict LRFS. Specifically, individuals had inferior AJCC/CAP TRG categories, low-differentiated differentiation, ypT3-4, or ypN$^+$ stage and displayed a high propensity to poor LRFS (all $P < .001$). Importantly, patients who did not receive neoadjuvant radiotherapy were more likely to develop local relapse ($P = .027$). Also, subgroup patients with tumors located at 5-10 cm from anal verge tended to
obtain a better LRFS, whereas those with tumors at 0-5 cm or > 10 cm were prone to have an inferior LRFS ($P = .004$).

### 4 | DISCUSSION

In the function-preserving strategy era, the concept of replacing neoadjuvant radiochemotherapy by systemic neoadjuvant chemotherapy was raised for LARC, as neoadjuvant radiotherapy only helps to control local recurrence in patients who are at risk of acute and long-term radiation-related toxicity. Moreover, the high quality of TME surgery also makes the pelvic recurrence rate low. However, whether and to what extent nCRT could be replaced by nCT has not yet been addressed. Here, by summarizing consecutive large size patient groups and using the propensity score matching method, the survival outcomes for the subgroup patients treated with nCRT and nCT were compared. Compared with previous studies,3,4,18-21 we found that although 3-y OS and DMFS were not improved, adding radiotherapy to nCT still minimized the pelvic recurrence for patients with LARC. Stratified analysis further confirmed that the neoadjuvant radiotherapy-improved LRFS was mainly observed in baseline cIII, cT4, and cN+.
stage subgroup patients. Importantly, this prolonged 3-y LRFS was consequently translated into a higher 3-y DFS. Therefore, even in the TME surgery era, neoadjuvant radiotherapy is still important to control pelvic relapse and could not be replaced by systemic nCT for baseline high-risk LARC patients.

Previously, side effects caused by neoadjuvant radiotherapy, such as fecal incontinence, sexual dysfunction, bowel dysfunction, and secondary malignancy, have been the major concern of physician and patients, due to the resulting impairment in quality of life.\textsuperscript{4,22-26} Actually, our recently phase III FOWARC trial confirmed that neoadjuvant radiotherapy-induced side effects were acceptable.\textsuperscript{10} Compared with the mFOLFOX6 subset, a slightly higher grade 3-4 hematologic, diarrhea, radiation dermatitis and proctitis toxicity were observed in the nCRT subgroup. Although higher grade 3 to 4 levels of leukopenia (19.0% vs 5.7%) and neutropenia (16.6% vs 9.0%) occurred in the mFOLFOX6-radiotherapy subgroup patients compared with the mFOLFOX6 subgroup patients, leukopenia and neutropenia were easily managed by G-CSF treatment. Significantly, neoadjuvant radiotherapy-induced post-operative complications, particularly anastomotic leakage, clinical fistula, and perineal infection, which were also well tolerated and associated with high treatment compliance. Moreover, treatment-related deaths did not occur, even in the nCRT subgroup that had a higher ratio of cT4b patients. Therefore, neoadjuvant

![Kaplan-Meier curve analysis of overall survival (A), disease-free survival (B), distant metastasis-free survival (C) and locoregional relapse-free survival (D), comparing the clinical T4 stage rectal cancer subgroup patients with or without neoadjuvant radiotherapy after propensity matching (1:4). nCRT, neoadjuvant chemoradiotherapy; nCT, neoadjuvant chemotherapy](image-url)
radiotherapy-caused side effects might be overestimated for LARC.

In line with previous studies, here we confirmed that, compared with systemic nCT, nCRT treatment correlated with a favorable LRFS for LARC patients. Particularly, we identified that individuals at the cIII stage, cT4, or cN+ stage would most benefit from nCRT treatment. Importantly, adding neoadjuvant radiotherapy to nCT increased local control (Figure 1) and pCR ratio (17.3% vs 27.3%), which finally translated into favorable DFS. In our recent FOWARC trial, although high-risk cT4b and cN+ patients were more likely to be placed in the nCRT treatment arm, the nCRT subset still had an evidently higher pCR ratio than the systemic nCT subset (27.5% vs 6.6%, \( P = .005 \)). However, this sound pCR ratio difference was not translated into varied local control and DFS ratio. The underlying reason might be attributed to the limited patient size in each arm. As shown in the methods section of the FOWARC trial, the primary endpoint was 3-y DFS, which was estimated as 60.0% in the fluorouracil-radiotherapy group, while it was 75.0% in either the mFOLFOX6 or the mFOLFOX6-radiotherapy arms. This 15.0% 3-y DFS gap included 165 patients per arm that would be enough to meet the study design. Actually, even in the present study with a large patient size (3233 cases),
TABLE 2  Univariate and multivariate analysis of accumulative recurrence

| Parameter                        | Univariate analysis |                           | Multivariate analysis |                           |
|----------------------------------|---------------------|---------------------------|-----------------------|---------------------------|
|                                  | 3-y LRFS            |                           | 3-y LRFS              |                           |
|                                  | HR                  | 95% CI                    | P-value               | HR                        | 95% CI                    | P-value               |
| AJCC/CAP TRG                     |                      |                           |                       |                           |                           |
| 0                                | 0.163               | 0.084 to 0.317            | <.001                 | 0.149                     | 0.075 to 0.297            | <.001                 |
| 1                                | 0.405               | 0.257 to 0.639            | <.001                 | 0.409                     | 0.258 to 0.648            | <.001                 |
| 2                                | 0.693               | 0.480 to 0.999            | .050                  | 0.669                     | 0.463 to 0.968            | .033                  |
| 3                                | 1                   | -                         | -                     | 1                         | -                         | -                     |
| Age, year                        |                      |                           |                       |                           |                           |
| ≤55                              | 1.480               | 1.098 to 1.996            | .010                  | 1.314                     | 0.968 to 1.784            | .158                  |
| >55                              | 1                   | -                         | -                     | 1                         | -                         | -                     |
| Gender                           |                      |                           |                       |                           |                           |
| Female                           | 1                   | -                         | -                     | -                         | -                         | -                     |
| Male                             | 1.152               | 0.833 to 1.592            | .393                  | -                         | -                         | -                     |
| Clinical T stage                 |                      |                           |                       |                           |                           |
| ct1                              | <0.001              | 0.000 to 8.916E + 10^9    | .945                  | -                         | -                         | -                     |
| ct2                              | 0.215               | 0.052 to 0.882            | .033                  | -                         | -                         | -                     |
| ct3                              | 0.772               | 0.561 to 1.063            | .113                  | -                         | -                         | -                     |
| ct4                              | 1                   | -                         | -                     | -                         | -                         | -                     |
| Clinical N stage                 |                      |                           |                       |                           |                           |
| cN0                              | 302.531             | 0.000 to 1.410E + 44      | .907                  | -                         | -                         | -                     |
| cN1                              | 442.869             | 0.000 to 2.064E + 44      | .901                  | -                         | -                         | -                     |
| cN2                              | 1                   | -                         | -                     | -                         | -                         | -                     |
| Clinical TNM stage               |                      |                           |                       |                           |                           |
| II                               | 0.732               | 0.515 to 1.042            | .084                  | -                         | -                         | -                     |
| III                              | 1                   | -                         | -                     | -                         | -                         | -                     |
| Location from anal verge, cm     |                      |                           |                       |                           |                           |
| 0-5                              | 0.857               | 0.471 to 1.558            | .612                  | 0.891                     | 0.490 to 1.620            | .705                  |
| 5-10                             | 0.513               | 0.275 to 0.957            | .036                  | 0.528                     | 0.283 to 0.986            | .045                  |
| >10                              | 1                   | -                         | 1                     | -                         | -                         | -                     |
| Tumor differentiation            |                      |                           |                       |                           |                           |
| High-differentiated              | 0.421               | 0.266 to 0.667            | <.001                 | 0.596                     | 0.366 to 0.972            | .038                  |
| Median-differentiated            | 0.390               | 0.272 to 0.558            | <.001                 | 0.523                     | 0.355 to 0.770            | .001                  |
| Low-differentiated               | 1                   | -                         | 1                     | -                         | -                         | -                     |
| Neoadjuvant RT or not            |                      |                           |                       |                           |                           |
| No RT                            | 1.450               | 1.044 to 2.013            | .027                  | 1.413                     | 1.007 to 1.983            | .046                  |
| RT                               | 1                   | -                         | 1                     | -                         | -                         | -                     |
| nCT cycle                        |                      |                           |                       |                           |                           |
| 1-4                              | 0.894               | 0.638 to 1.251            | .513                  | -                         | -                         | -                     |
| ≥5                               | 1                   | -                         | -                     | -                         | -                         | -                     |
| Pathological T stage             |                      |                           |                       |                           |                           |
| ypT0                             | 0.176               | 0.089 to 0.349            | <.001                 | 0.220                     | 0.106 to 0.457            | <.001                 |
| ypT1                             | 0.231               | 0.082 to 0.653            | .06                   | 0.298                     | 0.105 to 0.851            | .024                  |
| ypT2                             | 0.255               | 0.143 to 0.455            | <.001                 | 0.347                     | 0.192 to 0.627            | <.001                 |
| ypT3                             | 0.799               | 0.641 to 1.408            | .799                  | 0.993                     | 0.663 to 1.489            | .974                  |

(Continues)
the largest 3-y DFS difference was 10.1% (nCRT vs nCT, 78.1% vs 68.0%), which was only observed in the cT4 stage subgroup patients. Thus, neoadjuvant radiotherapy would confer survival benefit to baseline high-risk (cT4, cN+ and cIII stage) subgroup patients. By contrast, survival analysis revealed that neoadjuvant radiotherapy could be omitted for the baseline low-risk LARC subgroup patients (cT3, cN0, and cII stage). Together, the option to deliver neoadjuvant radiotherapy or not could be determined by their baseline risk category for patients with LARC.

We realize that our study had limitations. First, this was a retrospective study, and potential bias might be induced by confounding variables such as cTNM stage, chemotherapy regimen, and cycles. To minimize the potential bias, we recruited a consecutive and large size cohort patient. Using the propensity score matching model, the bias caused by confounding factors was minimized to the most extent. Significantly, our study did not include the neoadjuvant treatment complication information. As known, chemotherapy toxicities may increase the side effects of radiotherapy, which would affect the survival outcome.

In conclusion, using a propensity score matching model in large size LARC patients, our study confirmed that neoadjuvant radiotherapy might be omitted from nCRT for baseline low-risk LARC patients. Conversely, neoadjuvant radiotherapy is important to control pelvic recurrence and disease relapse for baseline high-risk LARC patients. This finding would be relevant for prospective PROSPECT (NCT01515787) and BACCHUS (NCT01650428) trials.

### TABLE 2 (Continued)

| Parameter                          | Univariate analysis |                        | Multivariate analysis |                        |
|------------------------------------|---------------------|------------------------|-----------------------|------------------------|
|                                    | 3-y LRFS            | 3-y LRFS               |                       | 3-y LRFS               | 3-y LRFS               |
|                                    | HR                  | 95% CI                 | P-value               | HR                    | 95% CI                 | P-value               |
| ypT4                               | 1                   |                        | 1                     | 1                     |
| Pathological N stage               |                     |                        |                       |                       |
| ypN0                               | 0.249               | 0.160 to 0.388         | <.001                 | 0.561                 | 0.344 to 0.916         | .021                 |
| ypN1                               | 0.761               | 0.476 to 1.218         | .256                  | 1.132                 | 0.691 to 1.853         | .624                 |
| ypN2                               | 1                   |                        | 1                     | 1                     |
| Pathological TNM stage             |                     |                        |                       |                       |
| ypT0N0                             | 0.123               | 0.064 to 0.237         | <.001                 | –                     | –                     | –                    |
| I                                  | 0.162               | 0.096 to 0.274         | <.001                 | –                     | –                     | –                    |
| II                                 | 0.503               | 0.364 to 0.694         | <.001                 | –                     | –                     | –                    |
| III                                | 1                   |                        | 1                     | 1                     |
| Vessel carcinoma embolus           |                     |                        |                       |                       |
| Positive                           | 1                   |                        | 1                     | 1                     |
| Negative                           | 0.366               | 0.208 to 0.645         | <.001                 | 0.659                 | 0.356 to 1.220         | .185                 |
| Surgical margin                    |                     |                        |                       |                       |
| Positive                           | 3.373               | 0.837 to 13.596        | .087                  | –                     | –                     | –                    |
| Negative                           | 1                   |                        | 1                     | 1                     |
| Tumor neural invasion              |                     |                        |                       |                       |
| Positive                           | 1                   |                        | 1                     | 1                     |
| Negative                           | 0.504               | 0.305 to 0.831         | .007                  | 1.187                 | 0.697 to 2.021         | .528                 |
| ACT or not                         |                     |                        |                       |                       |
| No ACT                             | 1.054               | 0.699 to 1.588         | .802                  | –                     | –                     | –                    |
| ACT                                | 1                   |                        | 1                     | 1                     |
| ACT cycle, median 4 cycle          |                     |                        |                       |                       |
| 0                                  | 0.950               | 0.605 to 1.492         | .823                  | –                     | –                     | –                    |
| 1-4                                | 1.069               | 0.774 to 1.475         | .686                  | –                     | –                     | –                    |
| ≥5                                 | 1                   |                        | 1                     | 1                     |
| Circumferential resection margin, mm|                     |                        |                       |                       |
| >1                                 | 1                   |                        | 1                     | 1                     |
| ≤1                                 | 0.213               | 0.079 to 0.574         | .002                  | 0.657                 | 0.234 to 1.848         | .426                 |

**Abbreviations:** 95% CI, 95% confidence interval; ACT, adjuvant chemotherapy; HR, hazard ratio; nCT, neoadjuvant chemotherapy; RT, radiotherapy.
ACKNOWLEDGMENTS
This study was supported by the Natural Science Foundation of China (No. 81872188, No. 8170112093), the International Centre for Genetic Engineering and Biotechnology Research Grant (No. CRP/CHN16-04_EC), and the Guangdong Natural Science Foundation for Distinguished Young Scholars (No. 2014A030306016).

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS
WXB and HF designed the study, HF performed contouring, treatment planning and the statistical analysis.YL, DY, WJ, ZJ, LS, PXL, CHY, JA and LZH reviewed the data. All authors discussed the data. WXB and HF drafted the manuscript. All co-authors read and approved the manuscript. All authors read and approved the final manuscript.

CONSENT FOR PUBLICATION
Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The protocol was approved by the ethics committee of the Sixth Affiliated Hospital, Sun Yat-sen University (No. 2019ZSLYE-137).

DATA AVAILABILITY STATEMENT
The datasets used during the current study are available from the corresponding author on reasonable request.

ORCID
Fang He https://orcid.org/0000-0002-8165-7914
Xiang-Bo Wan https://orcid.org/0000-0001-9437-6188

REFERENCES
1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
2. Kitz J, Fokas E, Beissbarth T, et al. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Surg. 2018;153:e181607.
3. Swedish Rectal Cancer T, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980-987.
4. van Gijn W, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575-582.
5. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124-5130.
6. Aschle C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773-2780.
7. O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927-1934.
8. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiation and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679-687.
9. Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979-989.
10. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol. 2016;34:3300-3307.
11. Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964-971.
12. Masi G, Vivaldi C, Fornaro L, et al. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur J Cancer. 2019;110:32-41.
13. NCCN. NCCN clinical practice guidelines in Oncology: Rectal Cancer. (version 2.2019).
14. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
15. von den Grün JM, Hartmann A, Fietkau R, et al. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. Radiother Oncol. 2018;128:557-563.
16. Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol. 2018;29:1521-1527.
17. Scalfani F, Brown G, Cunningham D, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016;27:1557-1565.
18. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Gimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644-5650.
19. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA. 2000;284:1008-1015.
20. Kapiteijn E, Marijn CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646.
21. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926-1933.
22. Peeters K, van de Velde C, Leer J, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-6206.
23. Bruheim K, Guren MG, Dahl AA, et al. Sexual function in males after radiotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys*. 2010;76:1012-1017.

24. Bruheim K, Guren MG, Skovlund E, et al. Late side effects and quality of life after radiotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys*. 2010;76:1005-1011.

25. Bruheim K, Tveit KM, Skovlund E, et al. Sexual function in females after radiotherapy for rectal cancer. *Acta Oncol*. 2010;49:826-832.

26. Lange MM, den Dulk M, Bossema ER, et al. Risk factors for faecal incontinence after rectal cancer treatment. *Br J Surg*. 2007;94:1278-1284.

27. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet*. 2009;373:811-820.

28. Deng Y, Chi P, Lan P, et al. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. *J Clin Oncol*. 2019;JCO1802309.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** He F, Yu L, Ding Y, et al. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. *Cancer Sci*. 2020;111:4205-4217. [https://doi.org/10.1111/cas.14636](https://doi.org/10.1111/cas.14636)